Amer Sports, Inc.

Fundamentals7.0
Price Action5.0
News Sentiment4.0
AI Rating
6.0

Key Drivers

  • Margin Improvement
  • Strong Cash Flow
  • Rich Valuation

AI
AI Summary

6.0

AS now looks like a high-quality growth compounder with strong brand momentum, improving margins, and solid cash generation, but the stock already prices in sustained execution so the main investment risk is that any slowdown in Arc'teryx/Salomon growth or margin expansion could trigger multiple compression rather than a business collapse.

Growth
ValuationRisk
Momentum‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

7.0

Key Financial Insights:

  • Margin Improvement
  • Strong Cash Flow
  • Rich Valuation

AS shows improving leverage, liquidity, and cash flow with solid but not exceptional profitability, but its rich valuation and intangible-heavy balance sheet limit upside.

CashFlow
Overvalued

Price Behavior

5.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Support defended
  • Overhead resistance
  • Lower-high trend

AS has been choppy but slightly higher over the last month, with buyers defending the low-$33 area and a rebound to $35.05 suggesting the chart may be stabilizing if it can reclaim the mid-$35s and clear $36.11-$36.83 resistance.

stabilization
rebound
Support Level: $33.30-$33.80
Resistance Level: $36.11-$36.83

Sharp mid-period decline followed by a two-day rebound to $35.05 signals volatile but stabilizing price action

Sentiment & News

4.0

Key News Insights:

  • Production ramp
  • EU approval step
  • No setbacks

Execution and product progress remain the common theme, with Lockheed Martin ramping defense production capacity and AbbVie clearing a key European regulatory milestone for RINVOQ.

Execution
RegulatoryProgress

The news is modestly positive for the instruments, signaling operational progress for Lockheed Martin and continued commercialization momentum for AbbVie